Revolution Medicines reported that its RAS inhibitor daraxonrasib met key endpoints in a pivotal phase 3 trial in previously treated metastatic pancreatic ductal adenocarcinoma, posting overall survival of 13.2 months versus 6.7 months with chemotherapy at an interim analysis. The company said the magnitude of benefit supported ending the study early. Revolution also noted it holds a US FDA “national priority” voucher in the program, which it said could accelerate time to a regulatory submission and approval trajectory. Wall Street coverage emphasized the readout’s potential to strengthen the case for RAS-pathway targeting in a disease where effective treatment options remain limited. The company’s next step is to prepare filings and communicate the full dataset with regulators and at upcoming scientific forums, while further clarifying which molecular subgroups drove the observed separation in outcomes.